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Several markers are available for evaluation and monitoring
of patients with breast cancer. Approximately 40-70% of
patients with metastatic disease have elevated CEA levels
(Haagensen et al., 1978; Hayes et al., 1986; Myers et al.,
1978; Tormey & Waalkes, 1978; Tormey et al., 1977), while
approximately 70-95% of such patients have elevated CA15-
3 levels. Moreover, serial CA15-3 levels are superior to CEA
for monitoring disease course (Fujino et al., 1986; Hayes et
al., 1986; Maigre et al., 1988; Pons-Anicet et al., 1987; Ton-
dini et al., 1988). Circulating levels of CA125 are elevated in
more than 80% of patients with epithelial ovarian carcinoma
(Alvarez et al., 1987; Bast et al., 1983; Canney et al., 1984;
Sekine et al., 1985) and antigen changes correlate with
disease course in these patients (Alvarez et al., 1987; Bast et
al., 1983; Canney et al., 1984; Niloff et al., 1985). CA125
levels have been reported to be greater than 35 U ml' in
only 12-18% of patients with breast cancer (Bast et al.,
1983; Kawahara et al., 1986). Using a higher cut-off of
65 U ml-', Omar and colleagues have reported elevated
CA125 levels in six of 33 patients (18%) with metastatic
breast carcinoma (Omar et al., 1989). However, little is
known about the correlation rate of this circulating antigen
with disease course in metastatic breast carcinoma.
Between October 1987 and December 1988, at least three
serial serum samples were collected from 40 consecutive
patients with breast carcinoma. In 11 patients the first sample
was drawn when metastases were diagnosed, before initiation
of any therapy for relapse. Twenty-nine patients had
previously received one or more modalities of treatment for
metastatic disease prior to collection of the first sample and
were monitored during a subsequent treatment regimen.
All patients were routinely staged before initiation of
therapy as follows: physical examination, alanine amino-
transferase (ALAT), aspartate aminotransferase (ASAT),
alkaline phosphatase (AP) and serum gamma glutamyl-
transferase (SGGT), complete blood count (CBC), chest and
bone radiographs, bone scan, and thoraco-abdominal CT-
scan. If thoracic CT-scan only was performed, then patients
had an abdominal evaluation with US. During follow-up,
physical examination was performed at least once a month.
ASAT, ALAT, AP and SGGT were performed each month.
Circulating antigens were assayed every 4 to 6 weeks at
physician discretion. Bone metastases were monitored by
standard radiographs and bone scans were performed only to
evaluate new bone or an increase of previously present bone
pain. Hepatic involvement was evaluated by abdominal ultra-
sound and/or CT-scan if ASAT, ALAT, AP or SGGT were
elevated. Clinical course was scored as progressive disease
(PD), stable disease (SD) or responsive disease (RD) accord-
ing to the WHO criteria for clinical evaluation (Miller et al.,
1981). Responsive disease included both complete and partial
responses.
Serum was stored at - 20'C until assayed for CA125,
CA15-3 and CEA. CA125 and CA15-3 were quantified by
immunoradiometric assays (Abbott CA125 kit, Abbott
Laboratories USA and CIS ELISA CA15-3 kit, Saclay, Gif-
sur-Yvette, France). CEA was determined by enzyme
immunoassay according to a procedure previously described
(Buchegger et al., 1982). For each marker, a cut-off value
was selected below which levels from 98.5% of healthy nor-
mal women are found (BAST et al., 1983; Hayes et al., 1986).
These cut-off levels may be compared since they provided
similar specificities in normal women and were as follows:
CA125, 35 U ml-'; CA15-3, 30 U ml-'; and CEA, 5.0 ng ml-'.
The variation between the antigen level measured at maxi-
mal clinical evaluation (AGm) and the initial antigen level
(AGj) was expressed as a percentage of the initial level. A
variation of the antigen levels of > 25% from the initial
antigen level was considered a significant change (Hayes et
al., 1986; Lokich et al., 1980; Tondini et al., 1988). If the
antigen levels never exceeded the cut-off value, then changes,
even if > 25%, were not considered to correlate with disease
course. The correlation between antigen level variation and
disease course was determined separately for PD, RD and
SD as previously described (Tondini et al., 1988). Among the
40 patients, 18 were scored as PD, 15 as RD and seven as
SD.
Before initiation of treatment in previously untreated
patients or before a change of treatment in previously treated
patients, CA125 levels were above 35 U ml-' in 16 of 40
patients (40%). CAl 5-3 was above 30 U ml' in 30 of 40
patients (75%) and CEA was above 5.0 ng ml' in 21 of 39
(54%) patients (one sample missing) (Table I). Although the
observed sensitivity of CA15-3 was higher, the differences
between the three assays were not statistically significant.
Median values of the circulating antigens drawn at first
evaluation were: 25.5 U ml' for CA125 (range 3.0-3,045);
94.5 U ml-' for CA15-3 (range 8.0-2,490) and 6.1 ng ml-'
for CEA (range 0.3-348). In three of the 24 patients with
Table I Sensitivity of circulating antigens in metastatic breast
cancer
Antigen
(cut-off)
CA125
(35 U ml-')
CA15-3
(30 U ml-')
CEA
(5 ng ml-')
Number of patients (%) with antigen levels
greater than or equal to cut-off level
16/40 (40%)-
30/40 (75%)
21/39b (54%)
aNo statistically significant differences between the assays. bOne
sample missing.
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CA125 level below the cut-off at the first determination,
CA125 increased >)25%, to a level above the cut-off, during
disease course. In the eight patients with RD and with a
decrease of CA125 levels of > 25%, the range of variation
was 45-98% (median 77%). The range of variation of
CA15-3 and CEA was similar in patients with RD (median
70% and 80% respectively). In the seven patients with PD
and with CA125 increase of > 25%, the range of variation
was 60-2,173% (median 668%). This is higher than the
median variation of CA15-3 and CEA in patients with PD
(94% and 142% respectively).
CA125 changes correlated with disease course in 17
patients (42.5%), while CA15-3 changes correlated in 24
patients (60%) and CEA changes in 16 patients (40%) (Table
II). Although CA15-3 had a higher correlation, the
differences between the correlation rates of the markers were
not statistically significant. The higher correlation with
disease course of CA15-3 levels compared to that of CEA is
consistant with previously published results (Hayes et al.,
1986; Pons-Anicet et al., 1987; Tondini et al., 1988). Interest-
ingly, the correlation with clinical course for CA125 was
similar to that for CEA. Correlations of each marker were
similar for PD and RD (Table II). All three circulating
antigens were poor indicators of SD. However, CA125 had
the highest correlation rate for SD (CA125, 28%, CA15-3,
14%; and CEA, 14%).
The correlation of each marker when used separately was
compared to combinations of any two, and to all markers
together. Combining CA125 and CA15-3 increased the cor-
relation rate to 72.5% compared to 42.5% for CA125 and
60% for CA15-3 alone. Combining CA15-3 and CEA
resulted in a modest increase in correlation rate to 67.5%
from 60% for CA15-3 and 40% for CEA alone. Combining
all markers together produced a correlation of 75%. Further-
more, although combining CA125 and CEA resulted in a
correlation rate greater than either of the two alone (55%),
this correlation was less than that of CA15-3 alone (60%).
The difference between the correlation of the combined cir-
culating antigens, either as doublets or all together, was not,
however, significantly different from the correlation rate of
CA15-3 alone. These results confirm the previous report that
combining CA15-3 with CEA did not enhance the clinical
utility of these markers in patients with metastic breast
cancer (Tondini et al., 1988). However, in three patients
CA125 was elevated and correlated with disease course while
CA15-3 was never elevated and of no utility. Thus, although
CA125 was not as commonly elevated in metastatic breast
carcinoma as CA15-3, when it was elevated the correlation
with disease course was as satisfactory as both CA15-3 and
Table II Correlation of antigen level variations with disease
course
Patients (%) with antigen level
variations that correlated with
Disease No. disease course
course patients CA125 CA15-3 CEA
PD 18 7 (39%) 11 (61%) 8 (44%)
RD 15 8 (53%) 12 (80%) 7 (47%)
SD 7 2 (28%) 1 (14%) 1 (14%)
Overall 40 17 (43%) 24 (60%) 16 (40%)
CEA. In this regard, CA125 may be useful in specific cases
when the other assays are not elevated.
Our results suggest that CA125 levels are more commonly
elevated in patients with metastatic breast carcinoma than
previously reported. In this study, CA125 was elevated in
40% of patients with metastatic breast cancer, almost three
times as high as in prior studies (Bast et al., 1983; Kawahara
et al., 1986). Furthermore, CA125 levels correlated with
disease course in 42.5% of patients. Our population may be
more representative of patients with metastatic disease since
CA15-3 and CEA levels parallel those of previous studies
(Hayes et al., 1986; Tondini et al., 1988). Although desig-
nated as a marker for ovarian cancer, CA125 is elevated in
other adenocarcinomas arising from the pancreas (45-59%)
(Bast et al., 1983; Haglund, 1986) and the gastrointestinal
system (49%) (Bast et al., 1983). Our results confirm that
CA125 cannot be used to distinguish sites of origin of meta-
static adenocarcinoma. Nor can the range of CA125 eleva-
tion be used to distinguish the origin of metastatic adenocar-
cinoma, since levels as high as 3,000 U ml- were seen in
patients with disseminated breast cancer. Serum CA125 levels
are also elevated in various benign diseases, including hepatic
cirrhosis, hepatic granulomatosis and peritonitis (Ruibal et
al., 1984), and in non-malignant pleural effusions (Pinto et
al., 1987). Our patients with elevated CA125 had no known
benign hepatic disease and two patients with chronically
abnormal hepatic function tests, attributed to benign
haemangiomas documented by CT-scan, had normal CA125
throughout their disease courses.
In summary, CA125 is more commonly elevated in meta-
static breast carcinoma patients than previously recognised
and can serve as a marker to monitor disease course if
CA15-3 is not elevated. However, the performance character-
istics of CA125 in breast cancer are not as satisfactory as for
CA15-3, which should be considered the marker of choice in
patients with disseminated breast carcinoma.
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